TSE:RIV

RIV Capital Competitors

C$2.10
-0.07 (-3.23 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
C$2.07
Now: C$2.10
C$2.15
50-Day Range
C$2.11
MA: C$2.64
C$3.37
52-Week Range
C$0.65
Now: C$2.10
C$3.60
Volume75,865 shs
Average Volume640,684 shs
Market CapitalizationC$293.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

RIV Capital (TSE:RIV) Vs. WLLW, LABS, KHRN, DN, META, and NRTH

Should you be buying RIV stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to RIV Capital, including Willow Biosciences Inc. (WLLW.TO) (WLLW), MediPharm Labs (LABS), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), Meta Growth (META), and 48North Cannabis (NRTH).

RIV Capital (TSE:RIV) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.

Profitability

This table compares RIV Capital and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RIV CapitalN/AN/AN/A
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for RIV Capital and Willow Biosciences Inc. (WLLW.TO), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RIV Capital01002.00
Willow Biosciences Inc. (WLLW.TO)0000N/A

RIV Capital currently has a consensus target price of C$4.00, indicating a potential upside of 90.48%. Willow Biosciences Inc. (WLLW.TO) has a consensus target price of C$2.25, indicating a potential upside of 74.42%. Given RIV Capital's higher probable upside, equities analysts clearly believe RIV Capital is more favorable than Willow Biosciences Inc. (WLLW.TO).

Valuation and Earnings

This table compares RIV Capital and Willow Biosciences Inc. (WLLW.TO)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RIV CapitalC$15.44 million19.03C$-106,223,568.00C($0.76)-2.77
Willow Biosciences Inc. (WLLW.TO)C$10,000.0015,901.57C$-51,032,952.00C($0.41)-3.12

Willow Biosciences Inc. (WLLW.TO) has lower revenue, but higher earnings than RIV Capital. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than RIV Capital, indicating that it is currently the more affordable of the two stocks.

RIV Capital (TSE:RIV) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Valuation and Earnings

This table compares RIV Capital and MediPharm Labs' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RIV CapitalC$15.44 million19.03C$-106,223,568.00C($0.76)-2.77
MediPharm LabsC$36.01 million3.44C$-123,815,040.00C($0.48)-1.00

RIV Capital has higher earnings, but lower revenue than MediPharm Labs. RIV Capital is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares RIV Capital and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RIV CapitalN/AN/AN/A
MediPharm LabsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for RIV Capital and MediPharm Labs, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RIV Capital01002.00
MediPharm Labs02023.00

RIV Capital currently has a consensus price target of C$4.00, indicating a potential upside of 90.48%. MediPharm Labs has a consensus price target of C$1.53, indicating a potential upside of 218.75%. Given MediPharm Labs' stronger consensus rating and higher possible upside, analysts plainly believe MediPharm Labs is more favorable than RIV Capital.

Summary

MediPharm Labs beats RIV Capital on 6 of the 8 factors compared between the two stocks.

RIV Capital (TSE:RIV) and Khiron Life Sciences (CVE:KHRN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for RIV Capital and Khiron Life Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RIV Capital01002.00
Khiron Life Sciences0000N/A

RIV Capital currently has a consensus target price of C$4.00, suggesting a potential upside of 90.48%. Khiron Life Sciences has a consensus target price of C$1.20, suggesting a potential upside of 122.22%. Given Khiron Life Sciences' higher probable upside, analysts plainly believe Khiron Life Sciences is more favorable than RIV Capital.

Earnings & Valuation

This table compares RIV Capital and Khiron Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RIV CapitalC$15.44 million19.03C$-106,223,568.00C($0.76)-2.77
Khiron Life SciencesC$8.01 million10.12C$-39,493,921.00C($0.26)-2.05

Khiron Life Sciences has lower revenue, but higher earnings than RIV Capital. RIV Capital is trading at a lower price-to-earnings ratio than Khiron Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares RIV Capital and Khiron Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RIV CapitalN/AN/AN/A
Khiron Life SciencesN/AN/AN/A

Summary

Khiron Life Sciences beats RIV Capital on 4 of the 6 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Delta 9 Cannabis and RIV Capital's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Delta 9 CannabisN/AN/AN/A
RIV CapitalN/AN/AN/A

Earnings and Valuation

This table compares Delta 9 Cannabis and RIV Capital's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$52.05 million1.14C$-7,339,680.00C($0.07)-8.06
RIV CapitalC$15.44 million19.03C$-106,223,568.00C($0.76)-2.77

Delta 9 Cannabis has higher revenue and earnings than RIV Capital. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than RIV Capital, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Delta 9 Cannabis and RIV Capital, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Delta 9 Cannabis00014.00
RIV Capital01002.00

Delta 9 Cannabis presently has a consensus target price of C$1.24, suggesting a potential upside of 113.79%. RIV Capital has a consensus target price of C$4.00, suggesting a potential upside of 90.48%. Given Delta 9 Cannabis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Delta 9 Cannabis is more favorable than RIV Capital.

Summary

Delta 9 Cannabis beats RIV Capital on 6 of the 8 factors compared between the two stocks.

Meta Growth (CVE:META) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares Meta Growth and RIV Capital's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66
RIV CapitalC$15.44 million19.03C$-106,223,568.00C($0.76)-2.77

Meta Growth has higher revenue and earnings than RIV Capital. RIV Capital is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Meta Growth and RIV Capital's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meta GrowthN/AN/AN/A
RIV CapitalN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Meta Growth and RIV Capital, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meta Growth0000N/A
RIV Capital01002.00

RIV Capital has a consensus price target of C$4.00, indicating a potential upside of 90.48%. Given RIV Capital's higher possible upside, analysts clearly believe RIV Capital is more favorable than Meta Growth.

Summary

Meta Growth beats RIV Capital on 4 of the 6 factors compared between the two stocks.

48North Cannabis (CVE:NRTH) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations for 48North Cannabis and RIV Capital, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
48North Cannabis0000N/A
RIV Capital01002.00

RIV Capital has a consensus price target of C$4.00, indicating a potential upside of 90.48%. Given RIV Capital's higher probable upside, analysts plainly believe RIV Capital is more favorable than 48North Cannabis.

Earnings and Valuation

This table compares 48North Cannabis and RIV Capital's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
48North CannabisC$17.36 million2.01C$-52,460,875.10C($0.26)-0.67
RIV CapitalC$15.44 million19.03C$-106,223,568.00C($0.76)-2.77

48North Cannabis has higher revenue and earnings than RIV Capital. RIV Capital is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 48North Cannabis and RIV Capital's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
48North CannabisN/AN/AN/A
RIV CapitalN/AN/AN/A

Summary

48North Cannabis beats RIV Capital on 4 of the 6 factors compared between the two stocks.


RIV Capital Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.29-3.1%C$159.02 millionC$10,000.00-3.12
LABS
MediPharm Labs
1.4$0.48-2.1%C$123.82 millionC$36.01 million-1.00Gap Up
KHRN
Khiron Life Sciences
0.9$0.54-3.7%C$67.34 millionC$8.01 million-2.05
DN
Delta 9 Cannabis
1.4$0.58-1.7%C$59.18 millionC$52.05 million-8.06
META
Meta Growth
0.8$0.14-0.0%C$36.69 millionC$60.96 million-0.66Gap Up
NRTH
48North Cannabis
0.7$0.18-8.6%C$36.44 millionC$17.36 million-0.67
CSI
(CSI)
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATT
Abattis Bioceuticals
0.5N/AN/AC$0.00N/A0.00Gap Down
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
IMCC
IM Cannabis
0.0N/AN/A$0.00N/A0.00High Trading Volume
PULL
Mind Cure Health
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
BUZZ
VanEck Vectors Social Sentiment ETF
1.0N/AN/A$0.00N/A0.00High Trading Volume
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.